Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3249354 | 0.85 | KDM4E (0.45) | MEN1KMT2AAKR1C3RXFP1GAA | |
| SCHEMBL3251453 | 0.83 | RXFP1 (0.43) | MEN1KMT2AAKR1C3RXFP1POLB | |
| Hydrochloric Acid SCHEMBL4163611 | 0.83 | KDM4E (0.39) | MEN1KMT2APKMRXFP1GAA | |
| SCHEMBL4170125 | 0.83 | KDM4E (0.47) | MEN1KMT2APKMRXFP1GAA | |
| Butyric Acid SCHEMBL4160300 | 0.80 | MEN1 (0.45) | MEN1KMT2ARXFP1TP53GAA | |
| SCHEMBL4161880 | 0.79 | BRD4 (0.43) | MEN1KMT2AGAA | |
| SCHEMBL3254812 | 0.79 | MEN1 (0.42) | MEN1KMT2ARXFP1TP53POLB | |
| SCHEMBL4159941 | 0.78 | JAK2 (0.38) | MEN1KMT2AGAAPOLB | |
| SCHEMBL3248958 | 0.78 | MEN1 (0.43) | MEN1KMT2ARXFP1TP53GAA | |
| SCHEMBL4162757 | 0.78 | CASP3 (0.37) | MEN1KMT2APKMGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | claimed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | claimed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | MEN1 3749/4885KMT2A 1882/4885PKM 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.